Cargando…
Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study
Autores principales: | de Gruijl, Tanja, Santegoeds, Saskia, van Wetering, Sandra, Singh, Satwinder Kaur, Hall, Anthony, van de Loosdrecht, Arjan A, Kruisbeek, Ada |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991268/ http://dx.doi.org/10.1186/2051-1426-1-S1-P205 |
Ejemplares similares
-
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
por: van de Loosdrecht, Arjan A., et al.
Publicado: (2018) -
Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade
por: Zuo, Haoxiao, et al.
Publicado: (2021) -
Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001
por: Janssen, Luca L.G., et al.
Publicado: (2023) -
Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells
por: Juillerat, Alexandre, et al.
Publicado: (2020) -
Allogeneic endometrial regenerative cells: An "Off the shelf solution" for critical limb ischemia?
por: Murphy, Michael P, et al.
Publicado: (2008)